SCHEDULE 13D: Reprogrammed Interchange and Reid Hoffman Acquire Significant Stake in VOR Biopharma, Secure Board Seat

Reprogrammed Interchange LLC and Reid Hoffman have acquired a 31.3% beneficial ownership stake in VOR Biopharma Inc. through a $38.75 million private placement, securing a board directorship and observer rights.

Summary

• Reprogrammed Interchange LLC and Reid Hoffman acquired 38,974,101 shares of Common Stock and warrants for 48,717,626 shares in VOR Biopharma Inc. as part of a private placement.
• The acquisition was part of a larger private placement where VOR Biopharma issued an aggregate of 55,871,260 shares and accompanying warrants for up to 69,839,075 shares to accredited institutional investors.
• Reprogrammed's total consideration for its stake was $38,749,999.92, funded by its working capital.
• The purchase price per share, including accompanying Common Stock Warrants, was $0.99425.
• The warrants are exercisable immediately at $0.838 per share and will expire seven years from the date of issuance, subject to an initial 9.99% ownership cap (changeable to 49.99% with 61 days' notice).
• The Reporting Persons now collectively beneficially own 38,974,101 shares, representing 31.3% of VOR Biopharma's Common Stock, calculated based on 68,673,612 shares outstanding as of November 1, 2024, plus the 55,871,260 shares issued in the private placement.
• As part of the December 2024 Securities Purchase Agreement, VOR Biopharma is required to appoint a designee of Reprogrammed, Erez Kalir, to its board of directors.
• Reprogrammed will also have a non-voting observer at board meetings as long as it beneficially owns 4.99% or more of the outstanding Common Stock.
• VOR Biopharma has agreed to file a Form S-3 registration statement within 30 days of the December 30, 2024, closing date to register the resale of the acquired shares and warrant shares.

Sentiment

Score: 7

Explanation: The document reports a significant capital infusion and strategic investment from a prominent investor, which is generally positive for a biopharma company's financial stability and future development. The securing of a board seat by the investor suggests a strong commitment and potential for strategic guidance. However, the transaction also involves substantial dilution for existing shareholders.

Positives

• Significant capital infusion for VOR Biopharma, with Reprogrammed Interchange LLC contributing approximately $38.75 million, providing crucial funding for operations and development programs.
• Strategic investment from a notable investor (Reid Hoffman, a Partner at Greylock Partners) and a private investment vehicle, signaling confidence in VOR Biopharma's prospects.
• The investment includes a board seat for Reprogrammed's designee, Erez Kalir, suggesting active engagement and potential strategic guidance from a significant new shareholder.
• The registration rights agreement facilitates future liquidity for the investors, which is a standard and positive provision for large private placements.

Negatives

• Significant dilution for existing shareholders due to the issuance of 55,871,260 new shares and accompanying warrants for up to 69,839,075 shares in the private placement.
• The purchase price of $0.99425 per share (with warrants) may represent a discount to the market price prior to the announcement, potentially indicating a lower valuation for the capital raise.

Risks

• The Reporting Persons may acquire additional securities or dispose of their current holdings in the future, which could impact the Issuer's stock price and market dynamics.
• Future actions by the Reporting Persons, including discussions with the Issuer's management and board regarding operations, strategic direction, governance, capitalization, or potential business combinations, could lead to significant changes in the Issuer's structure or strategy.
• The exercise of the Common Stock Warrants could lead to further dilution of existing shareholders if the warrant shares are issued.

Future Outlook

The Reporting Persons acquired the shares for investment purposes and currently have no plans to change control or dispose of securities. However, they explicitly state they may acquire or dispose of additional securities, engage in discussions with company management and the board regarding operations, strategic direction, governance, or capitalization, and potentially explore business combinations or dispositions involving the Issuer. VOR Biopharma is obligated to appoint a Reprogrammed designee to its board and file a registration statement for the resale of the acquired shares and warrant shares.

Management Comments

• Erez Kalir, the Reprogrammed Appointed Director, will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director.

Industry Context

This private placement represents a significant capital infusion into VOR Biopharma Inc., a common occurrence for development-stage biopharma companies that require substantial funding for research, clinical trials, and operational expenses. The involvement of a prominent venture capitalist like Reid Hoffman, a Partner at Greylock Partners, suggests a strategic belief in the company's long-term potential and aligns with broader industry trends of strategic investments in promising biotech ventures. The securing of a board seat further indicates a hands-on approach from the investor, which is typical in venture-backed companies aiming to guide strategic direction.

Comparison to Industry Standards

• The structure of this private placement, involving both shares and accompanying warrants, is a common financing mechanism utilized by biopharma companies to raise substantial capital, particularly when a full public offering might not be optimal.
• The warrant exercise price ($0.838) being lower than the share purchase price ($0.99425) is a typical feature in such deals, providing additional leverage and upside potential for the investors.
• The grant of a board seat and observer rights to a significant investor (holding a 31.3% stake) is standard practice in substantial private equity or venture capital investments, allowing for direct oversight and strategic input into the company's governance and operations.
• The inclusion of a registration rights agreement, obligating the company to register the shares for resale, is a customary provision in PIPE (Private Investment in Public Equity) transactions, ensuring a pathway for liquidity for the investors.
• The ownership cap on warrant exercise (initially 9.99%, changeable to 49.99% without triggering a change of control under Nasdaq rules) is a common protective measure to manage ownership concentration and regulatory compliance.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Experience significant dilution due to the issuance of new shares and warrants. However, they may benefit from increased capital stability and potential strategic guidance from a new, significant investor with board representation.
• **Employees:** Potential for increased stability and resources for company operations, research and development, and clinical programs due to the substantial capital infusion.
• **Management/Board:** Will experience increased oversight and strategic input from a significant new investor and board member, potentially leading to shifts in strategic priorities or operational focus.

Next Steps

• VOR Biopharma Inc. is required to appoint Erez Kalir as the Reprogrammed Appointed Director to its board of directors.
• VOR Biopharma Inc. must file a registration statement on Form S-3 within 30 days of December 30, 2024, to register the resale of the shares and warrant shares acquired in the private placement.
• VOR Biopharma Inc. must use reasonable efforts to have the Registration Statement declared effective within 75 days of its initial filing date.
• The Reporting Persons may, from time to time, acquire additional or dispose of existing Issuer securities based on various market and company factors.
• The Reporting Persons may engage in communications with Issuer stakeholders (stockholders, officers, board members, third parties) to discuss matters regarding operations, strategic direction, governance, or capitalization.

Key Dates

Recommendation

Keywords

VOR Biopharma, Reprogrammed Interchange LLC, Reid Hoffman, Private Placement, PIPE, Schedule 13D, Common Stock, Warrants, Beneficial Ownership, Board Appointment, Biopharma Investment, Venture Capital, Greylock Partners, SEC Filing